



Advanced Biomedical Research Goes Live with LabPas CT™

Montpelier, Vermont, October 8, 2007 – Advanced Biomedical Research, Inc. (ABR), an international, full-service CRO headquartered in Princeton, New Jersey, announced today that LabPas CT is live in their production environment and will be used to automate the conduct of their Phase I trials in their 72-bed research unit.

“ABR is committed to employing the latest information technology to perform, manage and monitor clinical trials in a cost-efficient and rapid manner,” said Dr. Michael Willett, President and CEO of ABR. “The adoption of LabPas CT has gone remarkably smoothly thanks to the combination of outstanding support from the LabPas staff and the efforts and incredible enthusiasm of our own clinical staff.”

John Rosenblum, President and CEO of Green Mountain Logic, developer of LabPas CT, noted, “ABR’s sophisticated and innovative approach to the conduct of clinical trials positions them at the leading edge of Phase I clinical trials.”

ABR is a full-service, Phase I-IV global CRO dedicated to meeting the needs of pharmaceutical, biotechnology, and medical device companies. ABR offers an extensive range of clinical services including clinical study design, strategic and regulatory consulting, project management, monitoring, clinical data management, biostatistics, pharmacokinetic and pharmacodynamic analysis, quality assurance auditing, medical writing, pharmacovigilance and regulatory submissions. ABR has tested numerous innovator and generic compounds in its state-of-the-art Phase I-II clinical research facilities in New Jersey and performs a wide range of clinical trials including first-in-human, dose escalation, proof of concept, bioavailability, bioequivalence, PK/PD, fed-fasted, drug-drug and drug-alcohol interactions and thorough or definitive QTc evaluations. ABR has also recently expanded its portfolio of services to include bioanalytical, formulation development, organic synthesis and clinical supplies release and stability testing through its partner, Frontage Laboratories. Further information about ABR is available at www.abr-pharma.com.

LabPas CT, the leading automation software for Phase I clinical trials, improves margins, decreases liability and increases clinical capabilities. Developed by Green Mountain Logic, the software comprehensively manages Phase I clinical trials, from recruiting through export to EDC. LabPas CT is unique in its ease of use and adaptability to individual study protocols. Further information about Green Mountain Logic and LabPas CT is available at: www.labpas.com.

Contact

Pat Sears
Vice President of Marketing
Green Mountain Logic
802.223.9800 ext. 120
psears@gmlogic.com